Podcast
MSL Talk: Tom Caravela, Alyson Evans
KPIs: Why Quantitative WON’T Work Without Qualitative Outcomes
Summary
In this episode, Linda Traylor and Rena Patel join Tom Caravela to share their insights on the evolving landscape of the MSL profession. They discuss the significance of networking, understanding KPIs, and the integration of qualitative outcomes to measure MSL value. The conversation highlights the adaptation of KPIs due to COVID-19 and the shift towards virtual engagement. The guests emphasize the importance of tactical planning and motivation strategies for MSL teams, along with lifelong learning and the benefits of MSL coaching. The episode concludes with tips for top performance and the necessity of continuous learning and adaptability in the field.
This episode is sponsored by IQVIA. www.iqvia.com
Linda Traylor, Sr Principal and Rina Patel, Director Medical Affairs at IQVIA discuss KPIs and the importance of qualitative Outcomes
Linda and Rina share…
👉 What are KPIs and why are they so important
👉 Does medical affairs have standards for KPIs
👉 Their approach to establishing KPIs and what is most important to track
👉 How medical affairs leaders align quantitative metrics with qualitative ones
👉 What qualitative outcomes should MSLs hope to achieve and why
👉 How the value of MSLs should be measured from a company perspective
MSL profession, networking in medical affairs, KPI integration, virtual engagement strategies, MSL coaching benefits
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Alyson Evans
Podcast
MSL Talk: Tom Caravela, Doug Yau
Emotional Intelligence and the MSL: More Important than EVER
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary